You are here: Industry Insights > INOVIO

News List

INOVIO Receives Orphan Drug Designation for Recurrent Respiratory papillomatosis Treatment americanpharmaceuticalreview
August 05, 2020
INOVIO announced the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).
INOVIO’s COVID-19 DNA Vax Effective in NHP contractpharma
July 31, 2020
INO-4800 effective in protecting non-human primates from live virus challenge 13 weeks after the last vaccination.
INOVIO Announces Positive Interim Phase 1 Data for INO-4800 Vaccine for COVID-19 americanpharmaceuticalreview
July 09, 2020
INOVIO announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.
Inovio’s COVID-19 vaccine candidate shows promise in small early-stage trial expresspharma
July 02, 2020
The vaccine induced immune responses in 34 of the 36 healthy volunteers aged 18 to 50 years, Inovio said.
Inovio gets $71 million from US defense department for COVID-19 vaccine device expresspharma
June 24, 2020
Inovio, which began human testing of its vaccine in April, said it expects to report interim results from the trial later this month, and added that it would begin mid-stage trials this summer.
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine americanpharmaceuticalreview
May 07, 2020
INOVIO has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG.
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today prnasia
April 07, 2020
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, pavi
INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine prnasia
March 12, 2020
The next generation CELLECTRA 3PSP device is designed specifically for a COVID-19 type pandemic scenario. It is a small, portable, hand-held, user-friendly device that runs on readily available "AA" batteries.
Inovio Provides Update on Clinical Program Plans for 2020 prnasia
January 06, 2020
Inovio Pharmaceuticals, Inc. announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical program goals for 2020 at the Biotech Showcase 2020 Conference in San Francisco, CA.
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer En-CPhI.cn
June 27, 2019
Inovio Pharmaceuticals announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial of VGX-3100

Previous page 1 2 3 4 5 Next page